SEATTLE, June 02, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and immunotherapy using the nCounter® platform that will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
"For more than 50 years the American Society of Clinical Oncology has been pioneering cancer research and advancing the care of patients with cancer around the world," said Brad Gray, president and chief executive officer of NanoString Technologies. "We are proud to participate in the ASCO Annual Meeting and to have the opportunity to highlight the groundbreaking cancer research and diagnostic assays that are being enabled through the nCounter platform and our expanding portfolio of 3D Biology™ products."
More than 30 abstracts will be presented at the ASCO Annual Meeting, which is being held June 3rd through June 7th, 2016 in Chicago, Illinois, that demonstrate the value of the nCounter Platform. In particular, several abstracts provide additional insights on the development and performance of NanoString’s investigational assays in development for immuno-oncology and lymphoma.
In immuno-oncology, NanoString and collaborators will present new details on nCounter-based assays under development for prediction of response to the checkpoint inhibitor pembrolizumab, including:
- An interferon-gamma gene signature was shown to predict response more accurately than PD-L1 IHC in squamous cell carcinoma of the head and neck. This research further demonstrates the power of gene expression profiling on the nCounter Analysis System as a biomarker in immuno-oncology. (Abstract #6010)
- An interferon-gamma gene signature and an expanded immune gene signature predicted response in five tumor types from the basket trial KEYNOTE-28, underscoring the potentially broad applicability of gene signatures in assessing patient response (Abstract #1536).
- Data on the development and analytical performance of an nCounter-based assay incorporating an immune-related gene signature to predict response to checkpoint inhibition in eleven different tumor types. The data show that this assay is robust and may be well-suited to clinical applications. The signature is being evaluated as a predictive biomarker in multiple indications in several studies (Abstract #3034).
In lymphoma, NanoString and collaborators are presenting results generated using nCounter-based assays, including:
- An update on the ongoing ROBUST trial, a global pivotal phase 3 trial evaluating the addition of lenalidomide to R-CHOP therapy in untreated ABC-type Diffuse Large B-cell Lymphoma (DLBCL) selected by NanoString’s investigational Cell-of-Origin assay. The results show that real-time testing of Cell-of-Origin using nCounter is feasible in a multi-center, global study with turnaround time of less than 3 days, demonstrating that a decentralized gene expression test can be used to select patients for a clinical trial where rapid results are critical for enrollment (Abstract #7538).
- Independent validation of the nCounter-based Cell-of-Origin assay through comparison to subtyping using DNA microarrays. The assay proved to be highly efficient and reliable in an independent series of samples evaluated by a team of researchers not involved in the development of the assay. This research highlights the high concordance between the NanoString assay and the conventional microarray method as well as the robustness and ease of use of the assay, which can be successfully deployed in laboratories around the world (Abstract #7547).
The 2016 ASCO abstracts describe research and clinical applications that underscore the diverse capabilities and robust performance of the nCounter platform. The studies cover a wide range of cancers, tissue types (FFPE, peripheral blood and urine), and treatment modalities.
At the 2016 ASCO Annual Meeting, NanoString will showcase its nCounter platform and 3D Biology capabilities at booth #8151.
|4525||Subclassification and outcome prediction of patients with muscle invasive urothelial carcinoma (MIUC) treated by radical cystectomy (RC) with a NanoString based molecular screening.||http://abstracts.asco.org/176/AbstView_176_167004.html|
|3034||Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.||http://abstracts.asco.org/176/AbstView_176_168736.html|
|3008||Epigenetic control of CD4/CD8 lineage commitment and resistance to tumor infiltrating lymphocyte adoptive cell therapy for metastatic melanoma.||http://abstracts.asco.org/176/AbstView_176_170003.html|
|6056||Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.||http://abstracts.asco.org/176/AbstView_176_169537.html|
|11522||Derivation of gene expression classifiers for the non-invasive detection of bladder cancer in the hematuria and recurrence surveillance populations.||http://abstracts.asco.org/176/AbstView_176_164671.html|
|e16014||Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets.||http://abstracts.asco.org/176/AbstView_176_169117.html|
|10561||Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors.||http://abstracts.asco.org/176/AbstView_176_168360.html|
|TPS3636||The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.||http://abstracts.asco.org/176/AbstView_176_169577.html|
|3038||Association of response to programmed death 1 receptor or ligand (PD1/PDL1) blockade with immune-related gene expression profiling across three cancer-types.||http://abstracts.asco.org/176/AbstView_176_170034.html|
|7045||Up-regulation of BAALC/MN1/MLLT11/EVI1 gene cluster in relation to MYC / BCL2 protein co-expression and poor overall survival in acute myeloid leukemia (AML).||http://abstracts.asco.org/176/AbstView_176_171325.html|
|e20089||Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.||http://abstracts.asco.org/176/AbstView_176_171299.html|
|e23235||Analysis of RSPO gene expression in solid tumors.||http://abstracts.asco.org/176/AbstView_176_170408.html|
|e14565||Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).||http://abstracts.asco.org/176/AbstView_176_170364.html|
|10509||Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.||http://abstracts.asco.org/176/AbstView_176_168561.html|
|e17103||Genomic profiling of high-intermediate risk endometrial cancer to differentiate recurrence risk.||http://abstracts.asco.org/176/AbstView_176_168355.html|
|3570||Influence of mRNA expression of fibroblast growth factor 2 (FGF2) in colorectal cancer (CRC) cell lines and in patients with metastatic colorectal cancer (mCRC) treated with FUFIRI or mIrOx (FIRE1).||http://abstracts.asco.org/176/AbstView_176_164113.html|
|7510||Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.||http://abstracts.asco.org/176/AbstView_176_163878.html|
|TPS7575||Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma.||http://abstracts.asco.org/176/AbstView_176_163751.html|
|7538||Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).||http://abstracts.asco.org/176/AbstView_176_162475.html|
|TPS7577||A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.||http://abstracts.asco.org/176/AbstView_176_165061.html|
|6010||Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).||http://abstracts.asco.org/176/AbstView_176_165708.html|
|e20014||The upregulation of FOXA2 transcription factor in RET rearranged lung adenocarcinoma.||http://abstracts.asco.org/176/AbstView_176_162380.html|
|e16023||PD1, PDL1, PDL2 tumor tissue (TT) expression as predictors of response to neoadjuvant chemotherapy (NAC) and outcome in bladder cancer (BC).||http://abstracts.asco.org/176/AbstView_176_167453.html|
|543||Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?||http://abstracts.asco.org/176/AbstView_176_166948.html|
|7547||Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.||http://abstracts.asco.org/176/AbstView_176_165721.html|
|1536||T-cell inflamed phenotype gene expression signatures to predict clinical benefit from pembrolizumab across multiple tumor types.||http://abstracts.asco.org/176/AbstView_176_168432.html|
|3510||Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.||http://abstracts.asco.org/176/AbstView_176_165798.html|
|1585||Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes.||http://abstracts.asco.org/176/AbstView_176_167604.html|
|575||A retrospective study of SPAG5 expression and its clinical implications in >8,000 patients of ER positive (ER+) breast cancer (BC): Genomic, transcriptomic and protein analysis.||http://abstracts.asco.org/176/AbstView_176_170849.html|
|569||Outcomes of single versus double hormone receptor positive breast cancer.||http://abstracts.asco.org/176/AbstView_176_169749.html|
|TPS623||OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.||http://abstracts.asco.org/176/AbstView_176_169580.html|
|e23143||The genomic profile (GP) of early breast cancer (EBC): Daily practice analysis.||http://abstracts.asco.org/176/AbstView_176_167027.html|
|555||A test utilizing diagnostic and on-treatment biomarkers to improve prediction of response to endocrine therapy in breast cancer.||http://abstracts.asco.org/176/AbstView_176_168226.html|
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact: Doug Farrell Vice President, Investor Relations & Corporate Communications email@example.com Phone: 206-602-1768